Top

Published in:

01-02-2011 | Review Article

Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease

Authors: Hironori Yokoyama, Hiroto Uchida, Hayato Kuroiwa, Jiro Kasahara, Tsutomu Araki

Published in: Neurological Sciences | Issue 1/2011

Abstract

Dopaminergic neurons are selectively vulnerable to oxidative stress and inflammatory attack. The neuronal cell loss in the substantia nigra is associated with a glial response composed markedly of activated microglia and, to a lesser extent, of reactive astrocytes although these glial responses may be the source of neurotrophic factors and can protect against oxidative stress such as reactive oxygen species and reactive nitrogen species. However, the glial response can also mediate a variety of deleterious events related to the production of pro-inflammatory, pro-oxidant reactive species, prostaglandins, cytokines, and so on. In this review, we discuss the possible protective and deleterious effects of glial cells in the neurodegenerative diseases and examine how these factors may contribute to the pathogenesis of Parkinson’s disease. This review suggests that further investigation concerning glial reaction in Parkinson’s disease may lead to disease-modifying therapeutic approaches and may contribute to the pathogenesis of this disease.

Olanow CW, Schapira AH, Agid Y (2003) Neuroprotection for Parkinson’s disease: prospects and promises. Ann Neurol 53(Suppl 3):S1–S2CrossRefPubMed

Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 991:1–14CrossRefPubMed

Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87CrossRefPubMed

McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23:474–483CrossRefPubMed

Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–145CrossRefPubMed

German DC, Manaye K, Smith WK et al (1989) Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 26:507–514CrossRefPubMed

Ma Y, Dhawan V, Mentis M et al (2002) Parametric mapping of [18F]FPCIT binding in early stage Parkinson’s disease: a PET study. Synapse 45:125–133CrossRefPubMed

Langston SW, Altman NS, Hotchkiss JH (1993) Within and between sample comparisons of Gompertz parameters for Salmonella enteritidis and aerobic plate counts in chicken stored in air and modified atmosphere. Int J Food Microbiol 18:43–52CrossRefPubMed

Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949–956PubMed

10.

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909CrossRefPubMed

11.

Bové J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson’s disease. NeuroRx 2:484–494CrossRefPubMed

12.

Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191–1206CrossRefPubMed

13.

Gluck MR, Youngster SK, Ramsay RR et al (1994) Studies on the characterization of the inhibitory mechanism of 4’-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles. J Neurochem 63:655–661CrossRefPubMed

14.

Sriram K, Pai KS, Boyd MR, Ravindranath V (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 749:44–52CrossRefPubMed

15.

Zigmond MJ, Stricker EM (1989) Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int Rev Neurobiol 31:1–79CrossRefPubMed

16.

Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469CrossRefPubMed

17.

Kurosaki R, Muramatsu Y, Kato H, Araki T (2004) Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson’s disease. Pharmacol Biochem Behav 78:143–153CrossRefPubMed

18.

Yokoyama H, Takagi S, Watanabe Y et al (2008) Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm 115:831–842CrossRefPubMed

19.

Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151–170CrossRefPubMed

20.

Damier P, Hirsch EC, Zhang P et al (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6CrossRefPubMed

21.

Wilkin GP, Knott C (1999) Glia: a curtain raiser. Adv Neurol 80:3–7PubMed

22.

Eddleston M, Mucke L (1993) Molecular profile of reactive astrocytes—implications for their role in neurologic disease. Neuroscience 54:15–36CrossRefPubMed

23.

Gehrmann J, Matsumoto Y, Kreutzberg GW (1995) Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20:269–287CrossRefPubMed

24.

Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7:111–118CrossRefPubMed

25.

Forno LS, DeLanney LE, Irwin I et al (1992) Astrocytes and Parkinson’s disease. Prog Brain Res 94:429–436CrossRefPubMed

26.

Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson’s disease. Neuroscience 95:425–432CrossRefPubMed

27.

Giulian D, Woodward J, Young DG et al (1988) Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490PubMed

28.

Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I et al (1988) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39:167–180CrossRef

29.

Liberatore GT, Jackson-Lewis V, Vukosavic S et al (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403–1409CrossRefPubMed

30.

Aoki E, Yano R, Yokoyama H et al (2009) Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 86:57–64CrossRefPubMed

31.

Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994) Neurotrophic factors: from molecule to man. Trends Neurosci 17:182–190CrossRefPubMed

32.

Tatton WG, Chalmers-Redman R, Brown D, Tatton N (2003) Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann Neurol 53(Suppl 3):S61–S70 (discussion S70–S72)CrossRefPubMed

33.

Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl 70:373–381CrossRefPubMed

34.

Mochizuki H, Mori H, Mizuno Y (1997) Apoptosis in neurodegenerative disorders. J Neural Transm Suppl 50:125–140PubMed

35.

Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150:119–131PubMed

36.

Hunot S, Brugg B, Ricard D et al (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94:7531–7536CrossRefPubMed

37.

Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130–1132CrossRefPubMed

38.

Saavedra A, Baltazar G, Santos P et al (2006) Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 23:533–542CrossRefPubMed

39.

Chen PS, Peng GS, Li G et al (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116–1125CrossRefPubMed

40.

Petrova P, Raibekas A, Pevsner J et al (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20:173–188CrossRefPubMed

41.

Hirsch EC, Hunot S, Damier P et al (1999) Glial cell participation in the degeneration of dopaminergic neurons in Parkinson’s disease. Adv Neurol 80:9–18PubMed

42.

Chen Y, Vartiainen NE, Ying W et al (2001) Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem 77:1601–1610CrossRefPubMed

43.

Dobrenis K (1998) Microglia in cell culture and in transplantation therapy for central nervous system disease. Methods 16:320–344CrossRefPubMed

44.

Kim WG, Mohney RP, Wilson B et al (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309–6316PubMed

45.

Ouchi Y, Yoshikawa E, Sekine Y et al (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175CrossRefPubMed

46.

Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412CrossRefPubMed

47.

Koutsilieri E, Scheller C, Grünblatt E et al (2002) Free radicals in Parkinson’s disease. J Neurol 249(Suppl 2):II1–II5PubMed

48.

Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 3(Suppl 3):S26–S36 (discussion S36–S38)CrossRef

49.

Jana S, Maiti AK, Bagh MB et al (2007) Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson’s disease. Brain Res 1139:195–200CrossRefPubMed

50.

McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54:599–604CrossRefPubMed

51.

Sugama S, Yang L, Cho BP et al (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964:288–294CrossRefPubMed

52.

Cicchetti F, Brownell AL, Williams K et al (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991–998CrossRefPubMed

53.

Depino AM, Earl C, Kaczmarczyk E et al (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur J Neurosci 18:2731–2742CrossRefPubMed

54.

Iravani MM, Kashefi K, Mander P et al (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110:49–58CrossRefPubMed

55.

Arimoto T, Bing G (2003) Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 12:35–45CrossRefPubMed

56.

Ryu JK, Shin WH, Kim J et al (2002) Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia 38:15–23CrossRefPubMed

57.

He Y, Le WD, Appel SH (2002) Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176:322–327CrossRefPubMed

58.

Qin L, Wu X, Block ML et al (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:453–462CrossRefPubMed

59.

Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson’s disease. Biochem Soc Symp 66:85–97PubMed

60.

McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291PubMed

61.

Burke RE, Antonelli M, Sulzer D (1998) Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 71:517–525CrossRefPubMed

62.

Kordower JH, Palfi S, Chen EY et al (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann Neurol 46:419–424CrossRefPubMed

63.

Gash DM, Zhang Z, Ovadia A et al (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252–255CrossRefPubMed

64.

Eberhardt O, Coelln RV, Kugler S et al (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci 20:9126–9134PubMed

65.

Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290:767–773CrossRefPubMed

66.

Frim DM, Uhler TA, Galpern WR et al (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 91:5104–5108CrossRefPubMed

67.

Levivier M, Przedborski S, Bencsics C, Kang UJ (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J Neurosci 15:7810–7820PubMed

68.

Przedborski S, Jackson-Lewis V, Djaldetti R et al (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135–142PubMed

69.

Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267:4904–4911CrossRefPubMed

70.

Benazzouz A, Piallat B, Ni ZG et al (2000) Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson’s disease. Cell Transplant 9:215–221PubMed

71.

DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281–285CrossRefPubMed

72.

Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol 84:100–104CrossRefPubMed

73.

Yamada T, McGeer PL, McGeer EG (1992) Some immunohistochemical features of argyrophilic grain dementia with normal cortical choline acetyltransferase levels but extensive subcortical pathology and markedly reduced dopamine. J Geriatr Psychiatry Neurol 5:3–13PubMed

74.

Hisahara S, Okano H, Miura M (2003) Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. Neurosci Res 46:387–397CrossRefPubMed

75.

Melcangi RC, Magnaghi V, Cavarretta I et al (1998) Effects of steroid hormones on gene expression of glial markers in the central and peripheral nervous system: variations induced by aging. Exp Gerontol 33:827–836CrossRefPubMed

76.

Tanaka J, Okuma Y, Tomobe K, Nomura Y (2005) The age-related degeneration of oligodendrocytes in the hippocampus of the senescence-accelerated mouse (SAM) P8: a quantitative immunohistochemical study. Biol Pharm Bull 28:615–618CrossRefPubMed

77.

Irving EA, Yatsushiro K, McCulloch J, Dewar D (1997) Rapid alteration of tau in oligodendrocytes after focal ischemic injury in the rat: involvement of free radicals. J Cereb Blood Flow Metab 17:612–622CrossRefPubMed

78.

McCracken E, Fowler JH, Dewar D et al (2002) Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502. J Cereb Blood Flow Metab 22:1090–1097CrossRefPubMed

79.

Gresle MM, Jarrott B, Jones NM, Callaway JK (2006) Injury to axons and oligodendrocytes following endothelin-1-induced middle cerebral artery occlusion in conscious rats. Brain Res 1110:13–22CrossRefPubMed

80.

Dewar D, Dawson D (1995) Tau protein is altered by focal cerebral ischaemia in the rat: an immunohistochemical and immunoblotting study. Brain Res 684:70–78CrossRefPubMed

81.

Imai H, Masayasu H, Dewar D et al (2001) Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 32:2149–2154CrossRefPubMed

82.

Vlkolinský R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 2′, 3′-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer’s disease. Neurobiol Aging 22:547–553CrossRefPubMed

83.

Takagi S, Hayakawa N, Kimoto H et al (2007) Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 114:1553–1557CrossRefPubMed

Title: Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease
Authors: Hironori Yokoyama
Hiroto Uchida
Hayato Kuroiwa
Jiro Kasahara
Tsutomu Araki
Publication date: 01-02-2011
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 1/2011
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-010-0424-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Postictal inhibition of the somatosensory cortex

Pursuit ocular movements in multiple sclerosis: a video-based eye-tracking study

BDNF Val66Met polymorphism and brain volumes in multiple sclerosis

The relevance of early TCD monitoring in the intensive care units for the confirming of brain death diagnosis

Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study